Toren, Paul http://orcid.org/0000-0002-5762-5787
Wilkins, Anna
Patel, Keval
Burley, Amy
Gris, Typhaine http://orcid.org/0000-0003-0347-8184
Kockelbergh, Roger http://orcid.org/0000-0003-2261-3628
Lodhi, Taha http://orcid.org/0000-0002-6891-0866
Choudhury, Ananya
Bryan, Richard T. http://orcid.org/0000-0003-2853-4293
Article History
Accepted: 17 July 2023
First Online: 21 August 2023
Competing interests
: P.T. reports research funding from AstraZeneca, as well as personal fees as a consultant from AbbVie, Bayer, Knight Pharmaceuticals, Tolmar and TerSera. A.W. and A.B. disclose funding received from AstraZeneca for a PhD studentship for A.B. supervised by A.W. A.W. discloses funding from imCORE for RE-ARM trial analysis. A.W. acknowledges funding from the RMH/ICR Cancer Research UK RadNet Centre. R.T.B. discloses research funding from Janssen, QED Therapeutics and UroGen Pharma, and consultancy for Nonacus Limited and Cystotech ApS. A.C. discloses funding from Cancer Research UK, National Institute of Health Research, Prostate Cancer UK, UK Research & Innovation, Elekta AB, honoraria from Bayer PLC, Janssen, AZ, ASTRO, ASCO, Roche and Merck, and is Editor in Chief of <i>BMJ Oncology</i>. A.C. is supported by the NIHR Manchester Biomedical Research Centre. The remaining authors declare no competing interests.